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In recent years, evidence has accumulated indicating that the enzyme arginase, which converts L-arginine into L-ornithine
and urea, plays a key role in the pathogenesis of pulmonary disorders such as asthma through dysregulation of L-arginine
metabolism and modulation of nitric oxide (NO) homeostasis. Allergic asthma is characterized by airway hyperresponsiveness,
inﬂammation, and remodeling. Through substrate competition, arginase decreases bioavailability of L-arginine for nitric oxide
synthase (NOS), thereby limiting NO production with subsequent eﬀects on airway tone and inﬂammation. By decreasing L-
argininebioavailability,arginasemayalsocontribute to theuncouplingofNOSandtheformationoftheproinﬂammatoryoxidant
peroxynitrite in the airways.Finally, arginasemayplay a role in the development ofchronic airwayremodeling through formation
of L-ornithine with downstream production of polyamines and L-proline, which are involved in processes of cellular proliferation
and collagen deposition. Further research on modulation of arginase activity and L-arginine bioavailability may reveal promising
novel therapeutic strategies for asthma.
1.Introduction
Sincetheidentiﬁcationofnitric oxideas abioactivemolecule
involved in the pathogenesis of pulmonary disorders, much
research has focused on the importance of the nitric oxide
synthase pathway involving conversion of L-arginine to
NO and L-citrulline. More recently, the arginase pathway
involving catabolism of L-arginine to L-ornithine and urea
has garnered attention for its potential role in arginine
dysregulation and alteration ofnitric oxidemetabolism, with
implications for the pathogenesis of airway diseases such as
asthma.
2.Asthmaand Arginine Dysregulation
Allergicasthma is achronicobstructivedisease oftheairways
characterized by airway hyperresponsiveness, inﬂamma-
tion, and remodeling. Inhalation of allergen immediately
induces the early asthmatic reaction (EAR) which involves
cross-linking of IgE by allergen, followed by activation of
cells bearing IgE receptor (predominantly mast cells and
basophils) with subsequent release of cytokines, proteases,
and proinﬂammatory mediators such as histamine [1, 2].
This rapid inﬂammatory cascade leads to vasodilation and
mucosal edema, mucus secretion, and contraction of airway
smooth muscle. The late asthmatic reaction (LAR) is an
intense IgE-mediated inﬂammatory response dominated by
inﬁltration of eosinophils and mononuclear cells that begins
three to nine hours after allergen challenge and is correlated
with intensity of associated bronchial hyperresponsiveness
[3, 4]. By 24–48 hours, TH2 cells elaborating cytokines
IL-4, IL-5, GM-CSF, and IL-13 can be found inﬁltrating
the inﬂamed airway, leading to further IgE production,
induction of vascular adhesion molecules, promotion of
chemotaxis, and eosinophil and macrophage activation [2].
Ongoing exposure to environmental allergens contributes to
chronic inﬂammation and may result in airway remodeling
characterized by hypertrophy of submucosal gland mass,
smooth muscle cell hyperplasia, and basement membrane
thickening due to subepithelial deposition of collagen [1,
5]. Such remodeling may lead to progressive loss of lung
function over time [1, 6, 7]. Recent evidence demonstrates2 Journal of Allergy
that arginase may play a role in arginine dysregulation which
contributes to the pathogenesis of asthma through eﬀects on
altered NO metabolism.
3.NitricOxideMetabolism and
AirwayFunction
Nitric oxide (NO) has been well described in the literature
as an important signaling molecule involved in regulation
of many mammalian physiologic and pathophysiologic pro-
cesses, particularly in the lung [8, 9]. NO plays a role in
regulation of both pulmonary vascular tone as well as airway
bronchomotor tone through eﬀects on relaxation of smooth
muscle. In addition, NO participates in inﬂammation and
host defense against infectionv i aa l t e r a t i o n si nv a s c u l a r
permeability, changes in epithelial barrier function and
repair, cytotoxicity, upregulation of ciliary motility, altered
mucus secretion, and inﬂammatory cell inﬁltration [10, 11].
These multiple functions of NO have been implicated in the
pathogenesis of chronic inﬂammatory airway diseases such
as asthma.
NO is produced by a family of nitric oxide synthases
(NOSs) that metabolize L-arginine through the interme-
diate N-hydroxy-L-arginine (NOHA) to form NO and L-
citrulline using oxygen and NADPH as cosubstrates. Three
NOS mammalian isoenzymes have been identiﬁed with
varying distributions and production of NO. Neuronal NOS
(nNOS or NOS I) and endothelial (eNOS or NOS III)
are constitutively expressed (cNOS) in airway epithelium,
inhibitory nonadrenergic noncholinergic (iNANC)neurons,
and airway vasculature endothelial cells. Their activity is
regulated by intracellular calcium, with rapid onset of
activityandproductionofsmall amountsofNOontheorder
of picomolar concentrations. Inducible NOS (iNOS or NOS
II)is transcriptionally regulatedbyproinﬂammatory stimuli,
with the ability to produce large amounts (nanomolar
concentrations) of NO over hours [11, 12].
iNOSis known tobe upregulated in asthmatic lungs, and
increased levels of exhaled NO are well described in asthma
patients [13, 14]. Supplemental oral or inhaled L-arginine
increases exhaled NOin bothnormal andasthmatic subjects,
indicating that the bioavailability of L-arginine for NOS
determines NO production within the airways [15–17]. In
guinea pig tracheal preparations, L-arginine has been shown
to inhibit airway hyperresponsiveness to methacholine and
to increase iNANC nerve-mediated airway smooth muscle
relaxation via increased production of NOS-derived NO
[18, 19]. Conversely, inhibition of NOS-derived NO by
N (G-) nitro-L-arginine methyl ester (L-NAME) ampliﬁes
bronchoconstriction in guinea pigs [20].
4.L-Arginine MetabolismDetermines
NOProduction
As the only substrate for NOS, L-arginine bioavailability
plays a key role in determining NO production and is
dependent on pathways of biosynthesis, cellular uptake,
and catabolism by NOS and arginase. Biosynthesis of the
semiessential amino acid occurs in a stepwise fashion.
L-glutamine and L-proline are absorbed from the small
intestine and converted to L-ornithine. L-citrulline is then
synthesized from L-ornithine by ornithine carbamoyltrans-
ferase (OTC) and carbamoylphosphate synthetase 1 (CPS1)
in hepatocytes as part of the urea cycle, as well as in
the intestine. L-arginine is produced from L-citrulline by
cytosolic enzymes argininosuccinate synthetase 1 (ASS1)
and argininosuccinate lyase (ASL). When L-arginine is
subsequently metabolized to NO via NOS, L-citrulline is
again produced and can be used for recycling back to L-
arginine, which may be an important source of L-arginine
during prolonged NO synthesis by iNOS [12].
The primary source of L-arginine for most cells is
cellular uptake via the Na-independent cationic amino acid
transporter (CAT) proteins of the y+-system. In particular,
upregulation of CAT-2B has been associated with increased
L-arginine uptakeunder conditions of iNOS induction stim-
ulated by proinﬂammatory mediators lipopolysaccharide
(LPS) and interferon-γ (IFN-γ)[ 21–26]. Ablation of the
CAT-2 gene is associated with impaired iNOS-mediated NO
synthesis in macrophages and astrocytes, which implies an
important role of CAT-2 in uptake of L-arginine substrate
for iNOS [27, 28].
L-arginine uptake via the y+-system can be inhibited by
other amino acids such as L-ornithine and L-lysine, as well
as by polycations such as eosinophil-derived major basic
protein (MBP) and poly-L-arginine [21, 29, 30]. MBP inhi-
bition of L-arginine uptake was associated with decreased
NO synthesis in rat alveolar macrophages and tracheal
epithelial cells, most likely related to reduced L-arginine
availability [24]. In addition, airway hyperresponsiveness
to methacholine has been shown to increase in rats and
guinea pigs after treatment with poly-L-arginine, related to
attenuation of epithelial NO production. Treatment with
combined poly-L-arginine and the antagonist polyanion
heparin restored L-arginine uptake and NO production and
reversed airway hyperresponsiveness [31–33].
5.Arginase andCatabolismof L-Arginine
More recently, focus has turned to the pathway of L-
arginine catabolism by arginase as important in regulating
endogenous NO production, with implications for airway
function in lung diseases such as asthma. Arginase is a
urea cycle enzyme that catalyzes the hydrolysis of L-arginine
to urea and L-ornithine. Both Arginase I and II isoforms
are constitutively expressed in the airways; Arginase I is
additionally located in the cytosol of hepatic cells, while
arginase II is mitochondrial and extrahepatic [12, 34].
While the aﬃnity (Km) of L-arginine for arginase is in
the low micromolar range compared to the low millimolar
range for NOS, substrate competition does occur between
arginase and NOS because the Vmax of arginase is 1000-
fold higher [35–37]. By competing for a common substrate,
arginase reduces the bioavailability of L-arginine for NOS,
thereforelimitingNOproduction.Speciﬁcarginaseinhibitor
N-hydroxy-nor-L-arginine (nor-NOHA) has been shownJournal of Allergy 3
Table 1: Pharmacologicenzyme inhibitors.
Inhibitor Speciﬁcity Route Reference
L-NAME Nonselective NOS Oral [20, 42, 43]
NOHA Arginase Inhaled [39, 44, 45]
nor-NOHA Arginase Inhaled,
intraperitoneal
[19, 38, 42, 46, 47]
L-NMMA Arginase Inhaled [48]
ABH Arginase Inhaled [49]
BEC Arginase Oropharyngeal
aspiration
[50]
Listofabbreviations:N(G-)nitro-L-arginine methylester(L-NAME),nitric
oxide synthase (NOS), N-hydroxy-L-arginine (NOHA), N-hydroxy-nor-
L-arginine (nor-NOHA), NG-monomethyl-L-arginine (L-NMMA), 2(S)-
amino-6-boronohexanoic acid (ABH),S-(2-boronoethyl)-l-cysteine (BEC).
to attenuate methacholine-induced constriction of guinea
pig trachea and to increase iNANC-mediated relaxation
of tracheal smooth muscle preparations, which is consis-
tent with increased NO production through NOS under
conditions of arginase inhibition [19, 38]( s e eTable 1 for
list of pharmacologic enzyme inhibitors). NOS can also
inhibit arginase activity through NOHA, the intermediate
in NO synthesis [39]. Arginase product L-ornithine may
also play a role in regulating availability of L-arginine to
NOS through competitive inhibition of arginase [37, 40,
41] as well as inhibition of L-arginine uptake by CATs of
the y+-system [21, 29, 30]. L-ornithine also serves as a
substrate for ornithine decarboxylase (ODC), which synthe-
sizes polyamines involved in promotion of cell growth and
repair, and for ornithine aminotransferase (OAT), leading
to formation of L-proline which is required for collagen
synthesis [12].
6.TH1/TH2 RegulationofArginase and
iNOS inAsthma
Allergicasthma isclearlyacomplicatedinﬂammatory disease
involving many diﬀerent stages, cell types, cytokines, and
mediators which remain incompletely understood. Depend-
ing on the stage, diﬀerent inﬂammatory mediators are
released from the various cell types, with implications for
NOS/arginase activity and airway function. Mast cells and
basophils are involved in the EAR and secrete histamine
and TNF-α. Eosinophils play an important role in the LAR
and contribute to ongoing inﬂammation through secretion
of cytotoxic major basic protein and eosinophilic cationic
protein. T cells are also key players in the pathophysiology
of asthma, with the TH1/TH2 balance well described as
being weighted towards the TH2p a t h w a y .T H1 cells (which
secrete IL-2, IFN-γ,a n dT N F - β) are involved in macrophage
activation and cell-mediated immunity. TH2 cells (which
secrete IL-4, IL-5, IL-10, and IL-13) are involved in mast cell
and eosinophil activation, and humoral immunity [2, 51].
The balance of iNOS versus arginase activity and level
of NO production in the airway may be related to the
balance of TH1/TH2 cytokines during the inﬂammatory
cascade. Experimental models of asthma have demonstrated
that iNOS is induced by proinﬂammatory TH1c y t o k i n e s
released from mast cells (such as TNF-α,I F N - γ,a n dI L - 1 )
after allergen challenge and during the LAR [9, 14, 52, 53].
Arginase activity is induced (and iNOS suppressed) by TH2
cytokines IL-4 and IL-10 in murine macrophages, although
IL-4 does not induce arginase in human macrophages
unless combined with agents that increase cAMP [54–
56]. Arginase activity increases following challenge with
allergens such as ovalbumin, Dermatophagoides farinae,a n d
Aspergillus fumigatusinguineapigtracheal preparations,and
inmouseandratmodelsofallergicasthma[44,57–61].Gene
expression studies have also shown induction of arginase I
more than arginase II gene expression in mouse models of
allergen-challenged lungs and TH2 cytokine-mediated lung
inﬂammation [59, 62–65].
7.Altered NOMetabolism andAirway
Hyperresponsiveness
In asthmatic patients as well as experimental models
of asthma, increased NO production occurs in the air-
ways related to upregulation of iNOS by proinﬂammatory
cytokines after allergen challenge and during the LAR
[9, 14, 52, 53]. This upregulation of iNOS in airway
epithelial cells and inﬂammatory cells is associated with
airway eosinophilia, airway hyperresponsiveness (AHR),
and increased NO in exhaled air [9, 16, 66–70]. Anti-
inﬂammatory treatment with corticosteroids reduces all of
these markers [71, 72]. The increased production of NO
may actually be a protective mechanism to maintain airway
tone in the setting of inﬂammatory changes. Studies of iNOS
knockout mice have demonstrated increased airway inﬂam-
mation and AHR compared to wild-type mice [46], whereas
mice that overexpress iNOS demonstrate increased exhaled
NO and decreased AHR without airway inﬂammation [73].
Airway inﬂammation in asthma may not be the result
of increased NO production itself, but rather due to the
formation of the proinﬂammatory oxidant peroxynitrite
from reaction of NO with superoxide anions in the air-
way. Peroxynitrite activates eosinophils, increases MUC5AC
expression, increases microvascular permeability, induces
airway epithelialdamage,andaugmentsairwaysmoothmus-
cle contraction [74–77]. Airway epithelial cells and inﬂam-
matory cells from bronchial biopsies of asthmatics as well
as allergen-challenged guinea pigs demonstrate increased
nitrotyrosine immunostaining (a marker for peroxynitrite
nitration of protein tyrosine), which is also correlated
with increased exhaled NO, iNOS expression, AHR, and
eosinophilic inﬂammation [75, 78, 79]. The AHR observed
after allergen challenge and the LAR may be the result of
increased peroxynitrite formation [74, 80].
8.Arginine DysregulationContributesto
AirwayHyperresponsiveness
In contrast to the increased NO production seen during
the LAR, the increased AHR seen after the EAR may4 Journal of Allergy
Table 2: Altered nitric oxide metabolism in allergic asthma.
Stage of allergic asthma∗
EAR LAR AHR Inﬂammation Remodeling
NO ↓↑↑ ↑ ↓ ?
cNOS ↓↔↔ ↔ ?
iNOS ↔↑ ↑ ↑ ?
Arginase ↑↑↑ ? ↑?
∗Productionof nitricoxide (NO) duringdiﬀerentstagesofasthmaisrelated
to the balance of NOS (nitric oxide synthase) and arginase activity. During
the early asthmatic reaction (EAR), increased arginase activity leads to
deﬁciency of L-arginine substrate for cNOS (constitutive NOS), thereby
decreasing NO production. iNOS (inducible NOS) is upregulated during
the late asthmatic reaction (LAR) leading to increased NO production, at
th esametimeasar gin aseacti vityin cr eases,an dairwa yh yperr espo n si v en ess
(AHR) increases. The availability of L-arginine substrate for both NOS
and arginase may drive reactions and can contribute to proinﬂammatory
peroxynitrite formation under low L-arginine conditions. Elevated NO and
iNOS are clearly associated with chronic allergic inﬂammation, but the role
of arginase in this stage is less apparent. At this time, little is known about
the roles of NO, NOS, and arginase during airway remodeling in asthma,
and further studiesare needed to elucidatethese pathways.
paradoxically involve NO deﬁciency within the airways
related to reducedbioavailability of L-arginine to both cNOS
and iNOS.
In guinea pig models of acute allergic asthma, exhaled
NO drops during the allergen-induced EAR, and iNOS
is not detected until the LAR, indicating that decreased
cNOS production of NO may contribute to subsequent
AHR [67, 81–83]. Table 2 describes the relative activity
of NOS and arginase with respect to the various stages
of allergic asthma. In patients with severe asthma and
evidence of AHR treated with corticosteroids, inhaled NOS
inhibitor NG-monomethyl-L-arginine (L-NMMA) failed to
potentiate bradykinin-mediated bronchoconstriction. The
authors concluded that this eﬀect reﬂected corticosteroid
downregulation of iNOS, with reduced cNOS-derived NO
leading to failure of bronchoprotection and increased AHR
[48].
Reduced L-arginine bioavailability to cNOS may be
responsible for the NO deﬁciency seen after the allergen-
induced EAR, as animal studies supplementing L-arginine
have shown decreased airway hyperresponsiveness after the
allergen-induced EAR. L-arginine supplementation reduced
the AHR to methacholine and increased iNANC nerve-
mediated airway smooth muscle relaxation in guinea pig
tracheal preparations, as well as attenuating the AHR to
histamine after the EAR in vivo in guinea pigs [18, 47, 49].
Low L-arginine conditions may also lead to increased pro-
duction of peroxynitrite after the LAR by uncoupling iNOS,
allowing it to produce superoxide anions via its reductase
domain, which react with NO to form peroxynitrite [84].
Increasing L-arginine availability increases NO production
and decreases superoxide and peroxynitrite production in
macrophages [85].
9.Arginase and AirwayHyperresponsiveness
As arginase plays a role in regulating bioavailability of
L-arginine for NOS by competitive consumption of the
substrate, increased arginase activity may be responsible for
the AHR after the EAR and LAR. In allergen-challenged
mice, arginase activity is increased in the airways at the same
time as L-arginine and L-citrulline levels are decreased [86].
Arginase’s role in allergen-induced AHR is demonstrated
by animal studies involving inhibition of both arginase and
NOS. Perfused guinea pig tracheal rings treated with speciﬁc
arginase inhibitor nor-NOHA demonstrated normalization
of allergen-induced AHR, and this eﬀect was prevented by
coincubation with NOS inhibitor L-NAME, indicating that
arginase leads to AHR by decreasing cNOS-derived NO
production [42]. iNANC nerve-mediated NO production
and smooth muscle relaxation is also restored after the
EAR by treatment with nor-NOHA, to a similar level
also seen with L-arginine supplementation [47]. Another
speciﬁc arginase inhibitor (2 (S-) amino-6-boronohexanoic
acid or ABH) not only reverses AHR after the EAR and
LAR following histamine challenge in a guinea pig model
of acute allergic asthma but also prevents AHR when
delivered 30 minutes prior to the histamine challenge, most
likely related to increased NO production [49]. Similarly,
intraperitoneal treatment with nor-NOHA prior to repeated
allergen challenge reduced AHR to methacholine in mice
[46].
As noted above, arginase competition for L-arginine may
alsocontributetotheLARbyincreasingperoxynitriteforma-
tionthroughpromotionofuncouplingofiNOSunderlowL-
arginine conditions, thereby resulting in the AHR seen after
the LAR [57, 87]. Evidence for this relationship comes from
the lungs of D. farinae-challenged mice which demonstrate
increased nitrotyrosine staining and concomitant increased
expression of arginase and iNOS [44].
Studies in human asthma conﬁrm the importance of
arginase in the pathogenesis of experimental asthma. While
increased arginase activity in the sputum of asthmatic
patients was documented as early as 1980 [88], its role in
the pathophysiology of asthma was not further elucidated
until decades later. Increased arginase I activity, mRNA,
and protein expression have now been demonstrated in
inﬂammatory cells and airway epithelium from bronchial
biopsies, as well as bronchoalveolar lavage samples from
asthmatic patients [58, 59]. Single nucleotide polymor-
phisms (SNPs) in both arginase I and arginase II have
been associated with atopy, while SNPs in arginase II
were associated with increased risk of childhood asthma
[89]. Increased arginase activity has also been demon-
strated in the serum of asthmatic children experiencing
an exacerbation, at the same time as plasma L-arginine
levels and the arginine/ornithine ratio (a biomarker that
inversely correlates to arginase activity) were reduced.
Improvement in asthma symptoms corresponded tempo-
rally with reduction of arginase activity and increase in
plasma L-arginine levels and the arginine/ornithine ratio
[90]. The lung function of severe asthmatics (FEV1 and
FEV1/FVC) correlates directly with L-arginine bioavailabil-
ity, and inversely with serum arginase activity, indicating
that serum arginase activity reduces circulating L-arginine
levels which contribute to NO deﬁciency within the airways
[91].Journal of Allergy 5
10.Arginase and AirwayInﬂammation
Airway inﬂammation is a key problem in asthma and
remains the main therapeutic target for treatment of the
disease.Arginase expression hasbeendocumentedininﬂam-
matory cells of both animal models and humans, but models
ofarginase inhibitionhavenotyetrevealedaconsistenteﬀect
on inﬂammatory pathways. Human polymorphonuclear
cells and eosinophils constitutively express arginase I, which
is located in azurophilic granules and upon release plays a
roleinregulationofL-arginineconcentration,suppressionof
activation of T-lymphocytes and NK cells, and antimicrobial
activity [92]. Arginase is highly expressed in M2 alternatively
activated macrophages which are stimulated by IL-4 and IL-
13 cytokinesproducedby CD4+TH2 cells, CD8+ T cells, NK
cells, basophils, mast cells, and eosinophils [93, 94]. In con-
trast, classical activation of macrophages for cytotoxickilling
involvesa TH1 inﬂammatory pathway in which arginase may
play a detrimental role of limiting NO production. Arginase
from alternatively activated macrophages, however, may play
a role in resolution ofinﬂammation and wound healing via a
shift towards synthesis of proline and polyamines instead of
NO production [94–96].
Contradictory studies of arginase inhibition have
reported enhancement, attenuation, and no eﬀect on
inﬂammation in animal models [46, 49, 50, 97]a n dm a y
reﬂect issues speciﬁc to animal models of asthma in general
that often limit our understanding and treatment of asthma
[98]. Since chronic asthma is a disease unique to humans,
the fact that mice do not have asthma may contribute to the
conﬂicting reports that make the mechanistic translation
to human disease more of a challenge. Further studies are
needed to clarify these eﬀects and their implications in man.
In mice sensitized to ovalbumin, arginase inhibitor S-(2-
boronoethyl)-l-cysteine (BEC) increased peribronchiolar
and perivascular inﬂammation associated with increased
S-nitrosothiols and 3-nitrotyrosine but did not change
allergen-induced increases in diﬀerential cell counts or
cytokine levels in BAL samples [50]. Unfortunately, the
role of low arginine bioavailability and NOS uncoupling
as a plausible contributing factor to excess superoxide
production in this model is unknown. In another study,
arginase inhibitor nor-NOHA administration prior to
ovalbumin challenge in mice decreased total cell count in
BAL samples by 65% felt to be related to increased NO
production, whereas iNOS-knockout mice had an increased
inﬂammatory response to the ovalbumin challenge [46].
ABH administration to guinea pigs similarly inhibited
allergen-induced increases in BAL inﬂammatory cells
(eosinophils, macrophages, and total cells) by 50% [49].
Finally, in chimeric mice with arginase I−/− bone marrow, no
change was seen in basal or allergen-induced inﬂammatory
cell inﬁltration or BAL diﬀerential cell counts, indicating
that at least bone marrow-derived arginase I is not required
for development of lung inﬂammation in the mouse model
[97].
11.Arginase and Chronic AirwayRemodeling
Airway remodeling can be seen in asthma as a result
of chronic airway inﬂammation, and prevention of this
complication is a major goal for treatment. Eosinophilia,
TGF-β, and IL-13 are postulated to play a role in the process
of airway remodeling [99]. Arginase may also participate
in the development of airway ﬁbrosis via the pathway
of L-ornithine production, with subsequent synthesis of
polyamines (involved in promotion of cell growth and
proliferation) and L-proline (involved in collagen synthe-
sis). Indeed, alternatively activated macrophages expressing
arginase I have been implicated in diseases such as idiopathic
pulmonary ﬁbrosis [100]. Mouse models of lung ﬁbrosis
reveal a dose-dependent correlation between proﬁbrotic
factor TGF-β and arginase activity in lung tissue and
ﬁbroblasts [101]. In mouse models of bleomycin-induced
pulmonary ﬁbrosis, increased expression of arginase I and
II and decreased L-arginine availability are associated with
increasedcollagenIexpression[45].Inhibitionofarginase by
nonspeciﬁc inhibitor NOHA decreases TGF-β1-stimulated
collagen deposition [44, 45]. Another mouse model of
lung ﬁbrosis investigated the role of TGF-β upregulation
using transgenic mice expressing human TGF-β under the
control of the Clara cell promoter. Following treatment
with doxycycline, IL-13 was upregulated, macrophages were
activated via the alternative pathway, arginase I and II
expression and arginase activity were augmented, and pul-
monary ﬁbrosis increased [102]. Taken together, arginase
seems to play a role in the ﬁbrotic pathway induced by
TGF-β by metabolism of L-arginine to L-ornithine, leading
to downstream production of proline and polyamines, and
ﬁnally resulting in collagen deposition and ﬁbrosis.
Arginase may also play a role in airway remodeling and
ﬁbrosis by decreasing NO production through competition
for L-arginine, thereby reducing antiﬁbrotic and antismooth
muscle proliferation eﬀects of NO. Antiﬁbrotic properties
of NO are demonstrated in studies of increased allergen-
induced collagen deposition in the airways of guinea pigs
after treatment with NOS inhibitor L-NAME and increased
collagen deposition in allergen-challenged iNOS knockout
mice compared to wild type [43, 104]. NO limits prolif-
eration of human and guinea pig cultured airway smooth
muscle cells by inhibiting cell cycle progression [105–108].
Finally, arginase may itself contribute to smooth muscle
proliferation via synthesis of polyamines and subsequent
stimulation of cell proliferation [109–112].
12.Arginase and Novel Therapeutic
TargetsforAsthma
Increased understanding of the role of arginase in the
pathogenesis of asthma naturally leads to consideration of
novel therapeutic targets for treatment. As noted above,
animal models of speciﬁc arginase inhibition have demon-
strated prevention or reversal of airway hyperresponsiveness
associated with allergen challenge, and therefore further
development and study of inhaled arginase inhibitors may
be a promising area of research.6 Journal of Allergy
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Figure 1: Altered arginine metabolism in hemolysis: a path to pulmonary dysfunction. Dietary glutamine serves as a precursor for the de
novo production of arginine through the citrulline-arginine pathway. Arginine is synthesized endogenously from citrulline primarily via the
intestinal-renalaxis.Arginaseandnitricoxidesynthase(NOS)competeforarginine,theircommonsubstrate.Insicklecelldisease(SCD)and
thalassemia,bioavailabilityof arginineand NO are decreased by severalmechanismslinked to hemolysis.The release of erythrocyte arginase
during hemolysis increases plasma arginase levels and shifts arginine metabolism towards ornithine production, limiting the amount of
substrate available for NO production. The bioavailability of arginine is further diminished by increased ornithine levels because ornithine
and arginine compete for the same transporter system for cellular uptake. Despite an increase in NOS, NO bioavailability is low due to low
substrate availability, NO scavenging by cell-free hemoglobin released during hemolysis, and through reactions with free radicals such as
superoxide and other reactive NO species. Superoxide is elevated in SCD due to low superoxide dismutase activity, high xanthine oxidase
activity, and potentially as a result of uncoupled NOS in an environment of low arginine and/or tetrahydrobiopterin concentration or
insuﬃcient NADPH. Endothelial dysfunction resulting from NO depletion and increased levels of the downstream products of ornithine
metabolism (polyamines and proline) likely contribute to the pathogenesis of lung injury, pulmonary hypertension, and asthma in SCD.
This model has implications for all hemolytic processes as well as pulmonary diseases associated with excess arginase production. This
novel disease paradigm is now recognized as an important mechanism in the pathophysiology of SCD and thalassemia.Abnormal arginase
activity emerges as a recurrent theme in the pathogenesis of a growing number of diverse pulmonary disorders. Regardless of the initiating
trigger, excess arginase activity represents a commonpathway in the pathogenesis of asthma and pulmonary hypertension, reproduced with
permissionfrom the American Society of Hematology [103].
Restoration of L-arginine bioavailability to NOS through
exogenous supplementation of L-arginine is another poten-
tial therapeutic target, although a great deal of orally
administered L-arginine is metabolized to urea in the
liver. Its utility may be further limited by excess arginase
found in seurm during an acute asthma exacerbation in
humans [90], skewing metabolism away from NO towards
ornithine and its downstream metabolites, proline, and
polyamines. Combination therapy utilizing L-arginine with
an arginase inhibitor may circumvent this issue. Alterna-
tively, L-citrulline or L-glutamine (converted to citrulline by
the enterocytes) could be administered as a prodrug for L-
arginine, as citrulline is converted in the kidney to arginine
throughthe“intestinal-renal axis”[113],thusbypassing liver
metabolism by arginase. Interestingly, citrulline supplemen-
tation in a pilot phase II clinical trial in sickle cell patients
resulted in an increase in plasma L-arginine levels [114].
Preliminary results of pharmacokinetic studies using oral L-
glutamine have also demonstrated improvement in global
arginine bioavailability in patients with SCDand pulmonary
hypertension [115].
13.SickleCell Disease:
A UniqueAsthmaParadigm
Sickle cell disease (SCD) is an inherited hemoglobinopathy
thatcausesachronichemolyticanemia.Asthmaisacommon
comorbidity in SCD with a reported prevalence of 30–
70% [116–124]. The high frequency of asthma in this
population cannot be attributed to genetic predisposition
alone and likely reﬂects in part the contribution of overlap-
ping mechanisms shared between these otherwise distinct
disorders [90, 125]. There is accumulating evidence thatJournal of Allergy 7
dysregulated arginine metabolism and in particular elevated
arginase activity contributes to pulmonary complications in
hemolytic disorders that include SCD and the thalassemia
syndromes [103, 126–132]. As summarized in this review,
derangements of arginine metabolism are also emerging
as newly appreciated mechanism in both asthma [57, 90,
91, 133, 134] and pulmonary hypertension independent
of SCD [135–139]( Figure 1). Patients with SCD may
potentiallybeatrisk foran “asthma-like”conditiontriggered
or worsened by hemolysis-driven release of erythrocyte
arginase and low nitric oxide bioavailability [125, 127],
in addition to classic familial asthma [140]. An abnormal
methacholine challenge and airway hyperreactivity has been
documented in up to 78% of children with SCD tested
[141–143]. Of interest, a recent study of 99 children with
SCD found few typical features of asthma associated with
a positive methacholine challenge. Although methacholine
responsiveness was correlated to a higher serum IgE, there
was no relationship between responsiveness and FEV1%
predicted, FEV1/FVC% predicted, bronchodilatory reactiv-
ity, eNO, allergy skin tests, or eosinophil count. However,
increased methacholine responsiveness was strongly corre-
lated to higher plasma LDH [143], a biomarker of hemolysis
[144] robustly associated with erythrocyte-released plasma
arginase concentration [127, 144]. Given the association of
asthma with inﬂammation, oxidative stress and hypoxemia,
factors known to contribute to a vasculopathy in SCD, and
the consequences of these factors on sickle erythrocytes,
comorbidasthmawouldlikelycontributetoaviciouscycleof
sicklingandsubsequentcomplicationsofSCD[125].Indeed,
a growing body of evidence links asthma to complications
in SCD, including acute chest syndrome [145], stroke [120],
pulmonary hypertension [124], and early mortality [123].
Whether this is true “asthma” by the conventional deﬁnition
or an “asthma-like” co-morbidity speciﬁc to SCD remains
unknown but is a current topic of interest [125, 126, 140,
143]. It is likely that dysregulated arginine metabolism and
excess production of proline and polyamines contribute
to many forms of abnormal pulmonary function in SCD
and other hemoglobinopathies [125]. In fact, we may learn
a great deal about the asthma paradigm itself from the
“asthma-like” condition that frequently develops in patients
with SCD.
14.Conclusion
Recent research has revealed mounting evidence for a
causal role for arginase in the development of airway
hyperresponsiveness, airway inﬂammation, and chronic air-
way remodeling which comprise allergic asthma. The eﬀects
of arginase on nitric oxide metabolism are related to its
competitiveconsumption ofL-arginine, leading todecreased
NO production and increased peroxynitrite formation. In
addition, the arginase by-product L-ornithine contributes to
synthesis of polyamines and L-proline which play a role in
pathways of ﬁbrosis by contributing to cellular proliferation
and collagen deposition. Further research is warranted to
investigatearginaseandarginineaspotentialnewtherapeutic
targets for treatment of asthma.
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